Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes

Area of Science:

• Oncolytic virology
• Cancer gene therapy
• Immunomodulation

Background:

• Metastatic cancer remains a significant challenge, with current therapies often proving insufficient for complete eradication.
• Conditionally replication-competent adenoviruses offer a promising strategy for tumor oncolysis via cancer-specific replication.
• Limitations exist in single-agent approaches due to cancer's multi-pathway abnormalities and disseminated metastases.

Purpose of the Study:

• To review cancer terminator viruses (CTVs), a novel class of adenoviruses engineered for cancer therapy.
• To explore the mechanisms of CTVs, including cancer-specific replication and transgene expression.
• To discuss strategies for enhancing systemic delivery and therapeutic efficacy of CTVs.

Main Methods:

• Development of cancer terminator viruses (CTVs) with replication controlled by the progression-elevated gene-3 promoter.
• Engineering CTVs to express apoptosis-inducing and immunomodulatory cytokines: melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) or interferon-γ.
• Review of existing literature and research on CTVs, their delivery, and therapeutic potential.

Main Results:

• CTVs are designed to replicate specifically in cancer cells, leading to tumor cell lysis (oncolysis).
• The expression of mda-7/IL-24 or interferon-γ by CTVs can induce apoptosis and modulate the immune response against cancer.
• The review highlights the potential of CTVs as a dual-action therapeutic agent.

Conclusions:

• CTVs represent a novel and promising approach for cancer treatment, combining oncolysis with targeted gene delivery.
• Improving systemic delivery and enhancing the therapeutic efficacy of CTVs are critical areas for future research.
• This therapeutic strategy holds potential for overcoming limitations of current cancer treatments for metastatic disease.